🇺🇸 fIPV at 6-14-22 weeks of age, RotaTeq in United States

fIPV at 6-14-22 weeks of age, RotaTeq (fIPV at 6-14-22 weeks of age, RotaTeq) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

fIPV at 6-14-22 weeks of age, RotaTeq in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is fIPV at 6-14-22 weeks of age, RotaTeq approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for fIPV at 6-14-22 weeks of age, RotaTeq in United States?

Centers for Disease Control and Prevention is the originator. The local marketing authorisation holder may differ — check the official source linked above.